Hello, everyone. Nice to see you again. Hope your week is going well so far. Meanwhile, another busy day lies ahead, especially as the FDA panel meeting gets under way to review Avandia. So let's get started with a cup of stimulation and some interesting tidbits to help you along. Have a good one and stay in touch...
Vivus Diet Drug Faces FDA Skepticism (Associated Press)
Merck Starts Work On New Plant In China (People's Daily)
Lawsuits May Reveal More Avandia Data (Reuters)
Lilly To Cut 170 Manufacturing Jobs (Indianapolis Business Journal)
Global CSO Market To Hit $6.5B By 2015 (OutsourcingPharma)
Clinuvel Drug Offers Relief From Sensititivity To Light (Bloomberg News)
Latisse Faces Patent Challenge (The Wall Street Journal)
Bristol-Myers Starts Recall Of Coumadin (Associated Press)
Massachusetts Gift Law Faces Possible Appeal (Associated Press)
Roche Signs Biomarker Deal With Qiagen (PharmaTimes)
1 Comment
Good find, on the China/Merck news:
Last week, Merck announced the closing of 16 facilities around the world; eight of those were manufacturing sites. This week, the move to low cost regimes accelerates, as Merck breaks ground on a 750,000 square foot building-site in Hangzhou, China.
I imagine that this is very hard for the good people of Glasgow, Scotland to stomach.
Namaste